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Distinct X-chromosome SNVs from 
some sporadic AD samples
A. Gómez-Ramos1,2, P. Podlesniy1,3, E. Soriano1,4,5,6 & J. Avila1,2
Sporadic Alzheimer disease (SAD) is the most prevalent neurodegenerative disorder. With the 
development of new generation DNA sequencing technologies, additional genetic risk factors have 
been described. Here we used various methods to process DNA sequencing data in order to gain further 
insight into this important disease. We have sequenced the exomes of brain samples from SAD patients 
and non-demented controls. Using either method, we found a higher number of single nucleotide 
variants (SNVs), from SAD patients, in genes present at the X chromosome. Using the most stringent 
method, we validated these variants by Sanger sequencing. Two of these gene variants, were found in 
loci related to the ubiquitin pathway (UBE2NL and ATXN3L), previously do not described as genetic risk 
factors for SAD.
Alzheimer disease (AD) has been classified mainly into two types, namely early or late-onset AD (EOD or LOAD). 
In the former, the disease appears in the fifth or sixth decade of life whereas in the latter it usually appears after 
70 years of age. EOD cases are related to family inheritance of APP, PSEN1 and PSEN2 genes mutated at specific 
sites1. This type of AD is known as Familial Alzheimer Disease (FAD) and it accounts for only about 1% of total 
cases2. However, most of the remaining cases, LOAD, also known as Sporadic Alzheimer Disease (SAD), are of 
unknown origin, aging being the main risk for the disease. In addition, several environmental and genetic factors 
have been proposed as risk factors for SAD. It has been reported that the presence of variants in several suscep-
tibility loci increases the probability of developing the disease3. Among these, the variant 4 of APOE is the most 
prevalent genetic risk factor described to date4. Also, other genome-wide genes associated with SAD, have been 
linked not only to cholesterol metabolism, like APOE, but to other pathways related to immunity and endocytosis5. 
In addition, it has also recently been proposed that somatic gene variations acting on specific brain cells could 
be involved in the onset of the disease6. In this case, and in contrast to FAD, the variations are present only in 
neuronal tissues, being absent in peripheral ones6. These variations may arise from somatic mutations that take 
place during the development (or during adulthood) of the patient’s organism. Another study showed that the 
appearance of SNVs is not random throughout the genome but that there is a higher proportion of these variants 
at specific chromosomes7. The analysis in that study was done using a method that allows the differentiation of 
specific SNVs in a small population of cells in a given sample. However, the presence of other cells types lacking the 
SNV in the same sample can hinder the validation of these variants using other sequencing analyses like Sanger’s 
method. Thus, here, we used an alternative more stringent method to analyze DNA sequencing data from brain 
samples from SAD patients and non-demented controls.
Using the data obtained by Illumina technology sequencing, here we have applied three methods to process 
DNA sequencing data from brain exome samples, with the aim to identify the most suitable method for a further 
classical validation, using the Sanger method. A comparison of the results of the three methods has revealed a 
broad correlation among them as the three ones focused on the presence of SNVs specific to exomes of SAD 
patients located at specific chromosomes. Interestingly, we found an increased proportion of these SNVs in the 
X chromosome, a chromosome linked to some brain diseases8–10. Also, using the strictest of the three methods, the 
variations identified by Illumina technology sequencing have allowed successful validation by the Sanger method. 
Among these SNVs were those present at the X chromosome and located at ATXN3L and UBE2NL, two genes 
involved in the ubiquitin pathway11.
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Results
The proportion of the number of SNVs from SAD patients varies depending on their chromo-
some localization. Hippocampal exome sequencing of two male and three female SAD patients and 3 male 
non-demented controls, analyzed by method A (see methods), indicated the presence of specific SNVs. Thus, we 
studied the number of these SNVs present in the chromosomes of the eight subjects. Figure 1A shows a similar, 
but not identical pattern of SNVs per chromosome in the three non-demented controls (C1–C3). Also, for SAD 
(A1–A5) patients, a similar but not identical pattern of distribution of the SNVs along the chromosomes was found.
In a further step, we compared the average number of SNVs per chromosome in SAD patients and 
non-demented controls (Fig. 1B). Higher numbers of SNVs at the X chromosome were detected in the former 
(Fig. 1B, inset).
The difference in the number of SNVs in the X chromosome of SAD cases compared to controls may be attribut-
able to the disease; however, it could also result from the gender of the donors. In order to check this, we performed 
a similar analysis to the previous one, testing the number of exonic SNVs per chromosome in the samples. However, 
on this occasion we treated the samples discriminated by gender. Supplementary Figure 1A shows the difference 
in SNV distribution along the chromosomes for the average of all the samples from male SAD cases. A very sim-
ilar distribution to that observed in the previous case, in Fig. 1B, was detected, with a significant difference in the 
number of SNVs for the X chromosome in SAD samples (Suppl. Fig. 1A, inset). No such difference was detected 
when we compared the average number of SNVs per chromosome in for all the SAD samples grouped by gender 
(Suppl. Fig. 1B). No significant differences in the number of SNVs were appreciated for the X chromosome (Suppl. 
Fig. 1B, inset). When another two non-demented controls (C4 and C5, see Table 1) were tested, no differences were 
found between this additional control and the rest of them, having not SNVs in the loci in where Alzheimer-SNVs 
were found (see results for chromosome X in Supplementary Figure 4B and Supplementary Table 1).
Chromosomal distribution of SNVs present only in SAD samples, using the three methods. To 
identify the SNVs that could be related to SAD, we searched for those SNVs present in the exomes of SAD cases but 
not in non-demented controls. For this purpose, using a comparative analysis, we proceeded in two ways to deter-
mine those SNVs present only in SAD samples. In the first case (method B, Fig. 2B), we selected only those SNVs 
present in SAD samples after a previous selection of the variants that passed the hard filter parameters suggested by 
software developers (http://gatkforums.broadinstitute.org/discussion/2806/howto-apply-hard-filters-to-a-call-set, 
see methods). In the second approach, we obtained SAD-specific SNVs (method C, Fig. 2C) by analyzing the files 
containing the variants at a previous level, in such a way that the selection of SAD-specific SNVs was done before 
filtering, comparing the raw files containing the SNVs obtained after calling the variants. Having obtained the 
SAD-specific raw data, we continued in a similar way to method B. We chose to do the comparison at this level of 
the analysis rather than to proceed comparing the files after filtering in order to avoid false negatives. Thus, when 
we have compared the files containing SNVs at a raw level and selected only the data containing variants present 
in SAD files, we can ensure that these selected variants were exclusive to the disease, and if these selected data 
have not enough quality or are not real SNVs, they will not pass the subsequent process of selection of real SNVs 
(filtering), indicated in methods.
To compare the pattern of SAD-specific SNVs with those variants in all the SAD samples but not necessarily 
exclusive to this disease (method A), we plotted the chromosomal distribution of these variants for these three 
methods (Fig. 3B). We found a similar chromosomal distribution in the case of the SAD-specific SNVs (obtained 
by methods B and C) as well as those present in SAD samples but not exclusive to the disease (method A) (Fig. 3B). 
The proportion of SNVs for the X chromosome was higher for methods B and C than for method A (Fig. 3B, inset).
Chromosomal distribution of the SNVs common to all SAD samples, using methods B and C. In 
order to identify the SNVs specific to SAD, we chose the intersection set of variants common to all the files contain-
ing SNVs present in SAD cases but not in any of the controls (Fig. 4A). We proceeded in this way for both method 
B and C and calculated the number of SNVs for each chromosome in a similar way to previous figures. The SNV 
distribution pattern per chromosome varied in most cases (Fig. 4B). The proportion of SNVs per chromosome 
was higher in some cases, such as for the X chromosome and chromosome 19, SNVs found in chromosome 11 
varied in the opposite way. Taking into account that the X chromosome showed a higher proportion of SNVs in 
samples from SAD patients than in those from non-demented controls, we examined the characteristics of the 
variants specific to the former and the corresponding genes in which they were found. Using methods B and C, we 
obtained a total of 84 and 42 SNVs along all the chromosomes, respectively. All the SNVs detected by method C 
were also included in those identified by method B (Table 2).
Characteristics of the genes bearing SNVs exclusive to SAD samples and located at the X chro-
mosome. With respect to the SNVs found by means of method C, the most stringent approach, we detected 
42 exonic SNVs exclusive to SAD samples and therefore not present in any controls (see Table 2, in bold). Three 
of these SNVs were in loci present in the X chromosome, namely in ATXN3L (putative ataxin-3-like protein), 
COL4A6 (collagen type IV alpha 6), and UBE2NL (ubiquitin-conjugating enzyme E2N-like). The variation in 
UBE2NL adds a stop signal to the DNA sequence, causing a truncation in the protein (L89*). This alteration may 
affect the function of this gene. The variation in the COL4A6 sequence does not affect translation because it is a 
synonym change, while the variation in the locus of ATXN3L involves the replacement of a glycine by an aspartate 
residue in position 332 of the protein. Looking at Gene Ontologies, the two genes with SNVs in the X chromosome 
have biological processes annotations related to the ubiquitin-proteosome system. Therefore, ATXN3L is involved 
in protein de-ubiquitination11 while UBE2NL is an ubiquitin-conjugating enzyme12.We have used hippocampal 
samples to have both somatic and germiline variations. In some cases (when available), we have already sequenced 
blood samples. The comparison of neuronal with these non-neuronal tissues showed a very similar pattern for the 
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Figure 1. Number of exomic brain SNVs and their chromosomal distribution in sporadic Alzheimer disease 
patients and control subjects. (A) Chart showing the percentage of SNVs for each chromosome in samples from 
non-demented controls (C1–C3) and sporadic Alzheimer disease (SAD) patients (A1–A5). (B) The graphic shows 
the average percentage of SNVs found in the hippocampus for each chromosome for three non-demented control 
(C) and five SAD (A) samples. A significant difference in the number of SNVs was found for the X chromosome 
(inset). Error bars show standard deviation in each case and double asterisk is statistically significant (P < 0.001) 
compared with control cases. (C) Plot showing the difference between the average of the number of exonic SNVs 
per chromosome in samples from SAD patients and from non-demented controls.
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studied SNVs, being almost identical in both (see a representative result in Supplementary Figure 3). This result 
indicates that, at least in these cases, the SNVs have a germinal origin; this also could explain why some changes, 
sometimes, occur in non-neuronal tissues, during AD development13.
Validation of the SNVs specific to the exomes of SAD patients by a) alignment of the reads and 
b) Sanger sequencing. A further validation was done by Sanger’s sequencing, comparing exome regions of 
SAD patients with those of non-demented controls. Figure 5 shows a representative validation of the data obtained 
by method C. All the regions surrounding the SNVs that we checked showed a correct correlation between the 
alignments of the reads against the reference genome and with the results obtained by Sanger sequencing, in all 
cases being homozygous or heterozygous. Thus, the validation of the SNVs by Sanger sequencing was achieved 
only by method C (those that are in bold in Table 2, see supplementary Figure 3). Using method B, we found that, 
in most cases, the lack of alignments of the reads surrounding the SNVs resulted in false negatives in the control 
samples (not shown). This observation could be attributed to the fact that in this method the comparison between 
the files containing SNVs was performed after a strict filtering of the reads on the basis of their quality. This filtering 
procedure used in method B ensured high quality of the SNVs obtained. However, the validation tests by Sanger 
sequencing and alignments show that some of the SNVs isolated by this approach are not always specific to SAD, 
but they are also present in some non-demented controls (not shown). On the other hand, when the comparison 
between files containing SNVs was done at a previous level, before filtering (like method C), and the loci considered 
as SAD-specific are then filtered using the same criteria, we can expect to obtain high quality SAD-specific SNVs 
that can be validated by Sanger sequencing.
In all the cases (method C), we found a correct correlation between the loci checked by Sanger sequencing and 
those expected to correspond by alignment (Fig. 5).
Discussion
Here we compared three methods to analyze the DNA sequences of hippocampal exomes from SAD patients and 
non-demented controls. We examined the number of SAD-specific SNVs in the chromosomes. Method A (see 
methods) yielded a descriptive catalog of all the SNVs present in the chromosomes, following the recommended 
workflows for variant analysis using the software included in GATK (https://www.broadinstitute.org/gatk/guide/
best-practices). This approach is commonly used to obtain exonic SNVs; however, it does not indicate differences 
between exomes. Method B has been used in a similar way6 to determine somatic mutations present in neuronal 
but not in peripheral tissues of a single SAD patient. A more strict approach, method C, described in the present 
study, allowed us to identify SNVs exclusive to SAD patients by means of an alignment step, and to later validate 
them by Sanger sequencing. The description of this method C is probably one of the strengths of the present study; 
the limitation of our study could be related to the small sample size, which might reduce the statistical significance 
of our work.
In this study we used brain tissue, since in these samples we can not only identify variants that could be inherited 
but also we can look at the presence of somatic mutations present in neuronal but not in peripheral tissue. Our 
results reveal a major difference in SAD-specific SNVs present in the X chromosome. Curiously, this chromosome 
contains an excess of genes that are highly expressed in brain tissue8,14,15.
Also, variations in genes present in chromosome X have been related to some neuronal diseases. In this way, 
some genes present in the X chromosome, have been reported to participate in brain function and dysfunction 
mainly of X-linked forms of mental retardation8. Moreover, a higher number of cognition genes have been identified 
in the X chromosome than in comparable-length segments of autosomes8,10
The higher increase in chromosome X found for SNVs of SAD patients, and the fact that males have one copy of 
the X chromosome while females have two, could make males more susceptible to SAD. However, this notion is not 
supported by current data2, which indicate a higher prevalence of SAD among females. This discrepancy could be 
explained by other non-genetic risk factors balancing out16 the possible prevalence of X-linked risk factors in males.
Furthermore, the distribution of SAD-specific SNVs in the X chromosome appears to be random (supple-
mentary Figure 2).
COL4A6, ATXN3L and UBE2NL were among the genes in the X chromosome showing SNVs present in all 
the DNA samples from SAD patients. These three genes are expressed in the brain and they have functions that 
Code Gender Age Diagnose
A1 M 94 Alzheimer
A2 F 85 Alzheimer
A3 F 84 Alzheimer
A4 F 84 Alzheimer
A5 M 78 Alzheimer
C1 M 86 –
C2 M 64 –
C3 M 46 –
C4 F 87 –
C5 M 80
Table 1.  Characteristics of the donors of the samples used in this study. The table shows the gender, age and 
diagnose of the donors of the samples that were used in this work.
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could be related to SAD pathology. We compared the present data with previous loci detected in GWAS studies., 
We found that a SNV at ATXN3L, locus chrx:13337059, has been already reported (http://www.gwascentral.org/), 
whereas for COL4A6, no correlation was found with the previous 66 reported SNVs. This is compatible with 
the possibility that the SNVs described herein may arise from somatic mutations, although further analyses are 
required to confirm this possibility. For the 4BE2NL gene, no GWAs data are available. In relationship with SNVs 
resulting from somatic changes in AD, there are two recent studies reporting the presence of low allele frequency 
Figure 2. Methods used to determine SNVs. Representation of the three methods used to analyze individual 
and SAD-specific SNVs (present in sporadic Alzheimer disease (SAD) samples but not in non-demented 
controls). The three methods begin with the alignment of raw reads in FastaQ format and end with the raw data 
containing SNVs achieved after the variant calling process. From here, we used three alternative approaches 
to obtain individual or SAD-specific SNVs.(A) Scheme showing the method used to obtain individual exonic 
SNVs in the SAD (A1–A5) or non-demented control (C1–C3) samples (see methods). (B,C) Methods used to 
determine the presence of SAD-specific SNVs. The difference between the two methods is that in B the selection 
of SAD-specific SNVs was done after filtering variants using specific parameters (see methods) while in C this 
selection was done beforehand, using raw data obtained from variant calling. Method C proved more exact for 
the validation of the SNVs obtained by Sanger’s sequencing (see results). For a more detailed explanation, see 
methods.
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mosaic mutations in the brain of AD patients, both of them focused to scrutinize SNVs at the APP, PSEN1, PSEN2 
and MAPT loci17,18.
COL4A6 encodes one of the six subunits of type IV collagen. The amount of this collagen is significantly 
increased in the cerebral micro-vessels of subjects with SAD compared to age-matched controls19. Another type 
of collagen, collagen VI, protects neurons against Abeta toxicity20.
ATXN3L is a deubiquitinating enzyme expressed in brain and associated with Machado-Joseph disease21; 
however, whether this protein is related to SAD remains unclear. UBE2NL is another protein related to the 
ubiquitination-de-ubiquitination process. It is also expressed in brain and it participates in parkin-dependent 
mitophagy22, a process that can be dysregulated in AD.
Finally, we do not know whether these changes in ubiquitination-de-ubiquitination affect tau, a key protein 
in SAD pathology that can undergo ubiquitination as a post-translational modification23,24. Interestingly, using 
method B, we identified another gene, USP51, also related to ubiquitination, in all the SAD samples tested.
In summary, here we describe a new method to identify SNVs from exome DNA sequencing by Illumina 
techniques. These SNVs can be later validated by classical sequencing approaches like the Sanger. Using this novel 
method to compare SAD and control samples, we have identified new SAD-specific SNVs in genes present in the 
X chromosome of brain cells.
Methods
Characteristics of donors. The characteristics of non-demented controls and SAD-diagnosed donors are 
summarized in Table 1.
Brain tissue processing and genomic DNA extraction. Hippocampal and blood tissue samples were 
extracted and processed as described in6. Genomic DNA was extracted from hippocampal tissue samples of 
Figure 3. Number of SNVs present in sporadic Alzheimer disease patients and their chromosomal 
distribution. (A) Venn diagrams showing the part of the files containing SNVs considered specific to SAD 
samples. We selected those SNVs present only in SAD samples, which we refer to as Alz1–Alz5. (B) The 
graphic shows the average percentage of SNVs per chromosome from the five previously described samples of 
hippocampal exonic SAD-specific SNVs in Fig. 3A (Alz1–Alz5), obtained by methods B and C (described in 
Fig. 2B,C respectively). Also, the average of the number hippocampal exonic SNVs per chromosome obtained 
by method A (present in all SAD samples, but not necessarily exclusive to them) (described in Fig. 1B) is shown 
in order to facilitate comparison of the profiles obtained by the three methods. The inset included in this figure 
shows the values obtained for the X chromosome by the three methods. Note that the proportion of SNVs 
for this chromosome is even larger when the variants are SAD-specific (method B and C) than when they are 
present in but not exclusive to SAD samples (method A).
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donors who had been clinically and neuropathologically confirmed as SAD cases and from control donors 
with no neurological or neuropathological hallmarks of the disease. Brain tissue samples were obtained from 
two Spanish brain banks (Banco de Tejidos CIEN [BT- CIEN] and Biobanco del Sistema Sanitario Público de 
Andalucía). Donors gave their written informed consent and the tissues were obtained using protocols approved 
by the ethical committee of the Banco de Tejidos CIEN [BT- CIEN] and the Biobanco del Sistema Sanitario Público 
de Andalucía. Our protocols and methods were previously approved by the ethical committee of our center 
(Comité de Ética de la Investigación conjunto CNB-CBMSO, http://www.cnb.csic.es/~cei/). The methods were 
carried out in accordance with the approved guidelines. DNA was extracted using Qiagen kits and following 
the manufacturer’s instructions.
Sample processing for exome sequencing. A Covaris LE220 instrument was used to fragment 3 μ g 
of genomic DNA (from brain and blood) to an average size of 200 bp. Short insert libraries were obtained 
using the Illumina TruSeq DNA Sample Preparation Kit. Exonic sequences were enriched using NimbleGen 
Sequence Capture Human Exome 2.1M Array. Paired-end sequences of 91 nucleotides from each end were 
generated using an Illumina HiSeq 2000 instrument to an average of 50x coverage. Sequences were generated 
in FastaQ format.
Bioinformatic analysis. Our analysis was based on the recommended workflows and good practices for 
variant analysis using the software suite Genome Analysis Tool Kit (GATK). Samples in FastaQ format were 
aligned to the human reference genome version GRCh37 using the BWA aligner software25 with default param-
eters and were then preprocessed by removing duplicate reads using Picard software (https://broadinstitute.
github.io/picard/). Local realignment was performed around insertions and deletions (INDELs) in order to 
improve SNV calling in these conflictive areas (IndelRealigner from26. Base quality scores were then recalibrated 
using the BaseRecalibrator tool from GATK. Recalibrated samples in BAM format were used to call SNVs and 
INDELs simultaneously with the HaplotypeCaller algorithm from26. At this point, we applied three methods 
depending on the analysis of interest:
Figure 4. Chromosomal distribution of specific SNVs common to all samples from patients with sporadic 
Alzheimer disease. (A) In a similar way to that described in Fig. 3A, this Venn diagrams shows the part of the 
SNVs specific to sporadic Alzheimer disease (SAD) represented in Fig. 4B. We selected those hippocampal 
SNVs common to all SAD samples but absent in the controls. (B) This plot represents the distribution of the 
percentage of specific SNVs per chromosome common to all SAD samples (represented in previous Fig. 3A as 
Alz 12345) obtained by methods B and C (see text and methods).
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Chrom Pos ID Gene name
Codon 
change Aa change GT A1 GT A2 GT A3 GT A4 GT A5
chr1 22206649 rs989994 HSPG2 aAt/aGt N765S C/C C/C C/C C/C C/C
chr1 40923019 rs2272994 ZNF643 atG/atA M46I G/A G/A G/A A/A A/A
chr1 53320274 rs480299 ZYG11A gaG/gaT E76D T/T G/T T/T T/T T/T
chr1 150679033 rs1336900 HORMAD1 aCa/aTa T187I G/A G/A G/A G/A G/A
chr1 150727539 rs2230061 CTSS Cgg/Tgg R113W G/A G/A G/A G/A G/A
chr1 150808889 rs2228099 ARNT gtG/gtC V173 C/G C/G C/G C/G C/G
chr1 201047062 rs4915476 CACNA1S Ctg/Ttg L522 G/A G/A A/A G/A G/A
chr1 201047075 rs4915477 CACNA1S ggT/ggC G517 A/G G/G G/G G/G G/G
chr1 228402508 rs2776853 OBSCN Ctg/Ttg L513 C/T C/T C/T C/T C/T
chr1 247921100 rs1552812 OR1C1 ggA/ggC G203 T/G G/G G/G G/G T/G
chr2 72361960 rs2241057 CYP26B1 tTg/tCg L189S A/G A/G A/G A/G A/G
chr2 100916315 rs11123823 LONRF2 ggT/ggC G134 G/G A/G A/G G/G A/G
chr2 100917109 rs13006224 LONRF2 tcG/tcA S111 T/T C/T C/T T/T C/T
chr2 101010082 rs3748930 CHST10 acC/acG T232 C/C G/C G/C C/C G/C
chr2 101646144 rs3739015 TBC1D8 tcC/tcT S662 G/A G/A G/A G/A G/A
chr3 33138544 rs7614776 GLB1 Ttg/Ctg L12 G/G G/G A/G G/G G/G
chr3 119133183 rs3732413 ARHGAP31 Ggc/Agc G803S G/A A/A A/A A/A A/A
chr4 76489582 rs2306174 C4orf26 Gtt/Att V124I G/A G/A G/A G/A G/A
chr4 79387442 rs7660664 FRAS1 caC/caT H2370 C/T C/T C/T C/T C/T
chr4 159881479 rs9784569 C4orf45 caA/caG Q105 C/C C/C C/C T/C T/C
chr6 150067675 rs10872646 NUP43 gTa/gCa V47A A/G A/G A/G A/G A/G
chr6 160952838 rs3124784 LPA Cgc/Tgc R2016C G/A G/A G/A G/A G/A
chr7 100731829 rs6948536 TRIM56 gcT/gcC A412 T/C C/C T/C C/C T/C
chr7 150439500 rs759011 GIMAP5 gcC/gcT A127 C/T C/T T/T C/T C/T
chr8 144941181 rs7839934 EPPK1 Ctg/Gtg L2081V G/C G/C G/C C/C G/C
chr9 34729452 rs10115191 RP11-195F19.10 NA NA A/G A/G A/G A/G A/G
chr9 125239253 rs1962091 OR1J1 aAc/aGc N318S C/C C/C C/C T/C T/C
chr10 50532683 rs7921186 C10orf71 tTc/tCc F698S C/C C/C C/C C/C C/C
chr10 70405855 rs3998860 TET1 atA/atG I1123M G/G G/G G/G G/G G/G
chr10 91007360 rs1051338 LIPA Acc/Ccc T16P T/G T/G T/G T/G T/G
chr11 4790396 rs17324609 OR51F1 gCt/gTt A251V A/A G/A G/A A/A A/A
chr11 4790482 rs12792898 OR51F1 ttA/ttG L222 C/C T/C T/C C/C C/C
chr11 4790575 rs12788102 OR51F1 tgT/tgC C191 G/G A/G A/G G/G G/G
chr11 4824878 rs2053116 OR52R1 Tcc/Gcc S245A C/C A/C C/C C/C C/C
chr11 4825349 rs17327254 OR52R1 Ttc/Ctc F167L G/G A/G A/G G/G G/G
chr11 4842866 rs35003053 OR51F2 gAc/gGc D84G G/G A/G A/G G/G G/G
chr11 4870284 rs35918613 OR51S1 aCc/aGc T52S C/C G/C G/C C/C C/C
chr11 4944892 rs34583466 OR51G1 acC/acG T226 C/C G/C G/C C/C C/C
chr11 4944986 rs12796015 OR51G1 aTt/aCt I195T G/G A/G A/G G/G G/G
chr11 4945199 rs34742470 OR51G1 cGc/cAc R124H T/T C/T C/T T/T T/T
chr11 7949791 rs7933807 OR10A6 gTt/gGt V140G A/C A/C A/C C/C C/C
chr11 12525925 rs11547363 PARVA cgC/cgT R149 C/T C/T C/T C/T C/T
chr11 18422487 rs61736803 LDHA atC/atA I116 C/A C/A C/A C/A C/A
chr11 44940828 rs2291334 TSPAN18 Gtc/Atc V133I G/A G/A G/A G/A G/A
chr11 55872876 rs2512961 OR8H2 Cat/Tat H120Y T/T T/T T/T T/T T/T
chr11 56510623 rs513873 OR9G4 gTa/gCa V222A G/G G/G A/G A/G A/G
chr11 56510694 rs1397053 OR9G4 ccA/ccG P198 T/C T/C T/C T/C T/C
chr11 74862391 rs1944612 SLCO2B1 NA NA G/G G/G G/G G/G G/G
chr11 108175462 rs1801516 ATM Gat/Aat D1853N G/A G/A G/A G/A G/A
chr11 117266312 rs2305830 CEP164 aCc/aGc T962S C/G C/G C/G C/G C/G
chr12 109693982 rs3742023 ACACB caC/caT H1299 T/T C/T C/T C/T C/T
chr13 46946157 rs1408184 KIAA0226L Ggg/Agg G152R T/T C/T C/T C/T C/T
chr13 49776080 rs9316430 FNDC3A aaA/aaG K1044 A/G A/G A/G A/G A/G
chr14 64637147 rs7161192 SYNE2 ctC/ctA L2119 C/A A/A C/A C/A C/A
chr15 58838038 rs6084 LIPC acC/acG T163 C/G G/G C/G G/G C/G
chr15 78390909 rs12593575 SH2D7 Cgg/Tgg R206W C/T C/T C/T C/T C/T
Continued
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A) To obtain all the exonic SNVs from each individual (see Fig. 2A), all files containing raw variants were 
treated individually with a workflow based on GATK best practices (https://www.broadinstitute.org/gatk/guide/
best-practices). Briefly, raw variants in gVCF format were genotyped with GenotypeGVCF from26. Before filtration, 
only SNVs were selected from raw files and separated from INDELs with SelectVariants algorithm from26. The 
files containing raw variants were filtered using the following parameters: coverage: DP > 20, QD < 2.0; FS > 60.0, 
MQ < 35.0; HaplotypeScore > 13.0; MQRankSum < −12.5, ReadPosRankSum < − 8.0 and QUAL > 30. We 
selected only calls that passed these filters. The variants were then annotated using the dbSNP database version 
13827, the UCSC human RefGene26,28, and snpEFF software version 3.629.
B) In order to obtain variants present in the exomes of SAD patients, a similar method to that described in A 
was applied, but in this case comparing each file containing filtered and recalibrated exonic variants from SAD 
patients with those from control subjects and selecting only those SNVs present in SAD samples but absent in 
controls (see Fig. 2B). This was achieved using HTSlib/Samtools software30.
C) An alternative method was also used to compare files containing SNVs and to obtain those variants present 
only in SAD samples (see Fig. 2C). The difference between this method and the previous one is that the compar-
ison between SAD and control files was done at a previous level, when all the variants had not been filtered (raw 
variants). Using this approach, we prevented the loss of true SNVs and their appearance as false negatives. As in B, 
we selected only variants present in the SAD individuals but in none of the controls. Having completed this step, 
we proceeded by filtering, recalibrating, and annotating the SNVs obtained with the same software and parameters 
as in methods A and B.
GWAs data for human atxn3l, col4a6 and ube2 nl genes were obtained from http://www.gwascentral.org/.
Polymerase chain reaction (PCR) amplification and Sanger sequencing. To validate some of the 
results obtained by Illumina sequencing, we performed Sanger sequencing on PCR-amplified genomic DNA con-
taining the studied loci. The oligonucleotide primers ATX3NL_fw (5′ -TGCAGGCTCAAAAATCAAAGGA-3′ ) 
and ATX3NL_rv (5′ -TCCGGAAACACATCGCAAGA-3′ ) were used to amplify and then sequence a 539-bp 
Chrom Pos ID Gene name
Codon 
change Aa change GT A1 GT A2 GT A3 GT A4 GT A5
chr16 2812890 rs2240141 SRRM2 aaA/aaG K39 G/G G/G A/G G/G G/G
chr16 3490922 rs2270494 ZNF597 ctC/ctG L15 G/C C/C G/C C/C G/C
chr18 59936142 rs17645999 KIAA1468 gtC/gtT V907 T/T C/T T/T C/T C/T
chr19 2917612 rs10410539 ZNF57 acT/acC T299 C/C C/C T/C T/C T/C
chr19 18679379 rs7648 C19orf50 Cct/Gct P157A C/G G/G G/G G/G G/G
chr19 20748522 rs12979592 ZNF737 NA NA C/A C/A C/A C/A C/A
chr19 34959979 rs7259160 UBA2 tcA/tcG S496 A/G G/G G/G A/G G/G
chr20 13134768 rs6078938 SPTLC3 taT/taC Y466 C/C T/C T/C T/C T/C
chr20 55108617 rs3209183 C20orf107 Cag/Aag Q74K A/A A/A C/A C/A C/A
chr21 33887131 rs1129157 C21orf63 ccG/ccA P271 G/A G/A G/A G/A A/A
chr22 18209920 rs9306198 BCL2L13 Cct/Tct P198S T/T C/T C/T C/T C/T
chr22 32554985 rs5998267 C22orf42 cTg/cCg L73P G/G A/G A/G A/G A/G
chrX 13337059 rs4830842 ATXN3L gGc/gAc G332D C/T C/T C/T T/T C/T
chrX 55514818 rs3126255 USP51 gaG/gaA E185 C/T C/T C/T T/T T/T
chrX 70146398 rs4360450 SLC7A3 agT/agC S533 A/G G/G A/G G/G G/G
chrX 74494470 rs4892396 UPRT cgT/cgG R127 G/G G/G G/G G/G G/G
chrX 85219021 rs10217950 CHM gcA/gcG A117 T/C T/C T/C C/C C/C
chrX 88008807 rs5984611 CPXCR1 cGt/cAt R131H G/A G/A G/A G/A G/A
chrX 105153001 rs209372 NRK aaA/aaG K456 G/G G/G G/G G/G G/G
chrX 107417730 rs5973851 COL4A6 ggC/ggT G1026 G/A G/A G/A G/A G/A
chrX 114425400 rs12857270 RBMXL3 Gga/Aga G466R A/A G/A A/A A/A A/A
chrX 117700141 rs2286977 DOCK11 gcA/gcG A289 A/G A/G G/G A/G A/G
chrX 118604436 rs12390 SLC25A5 acT/acC T233 C/C C/C T/C T/C C/C
chrX 118699320 rs5910616 CXorf56 NA NA G/G G/G A/G G/G G/G
chrX 133379551 rs2428577 CCDC160 Cta/Tta L241 T/T T/T T/T T/T T/T
chrX 142967468 rs237520 UBE2NL tTa/tGa L89* T/G T/G T/G G/G G/G
chrX 144904882 rs2748588 SLITRK2 ccT/ccC P313 T/C C/C C/C C/C C/C
chrX 153633359 rs1130929 DNASE1L1 ccC/ccG P67 C/C C/C C/C C/C C/C
Table 2.  Characteristics of the SNVs present in all the samples from sporadic Alzheimer disease patients 
but not in the non-demented controls. This table shows the position in genome, ID in dbSNP26, name of the 
gene in which the SNVs are located, codon and amino acid changes (if any), and the genotypes (GT) for the 
SNVs specific to sporadic Alzheimer disease found in the five exomes analyzed. All the SNVs in the table (84) 
were obtained by method B. Those shown in bold (42 SNVs, included in those obtained by method B) were 
obtained by method C.
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fragment containing the SNV rs4830842 located in ATXN3L. The PCR products were electrophoresed in 1% 
agarose gel stained with Sybr Safe DNA gel stain (Life Technologies) and visualized under UV light. Sequencing 
was performed by Macrogen Europe (Amsterdam, the Netherlands).
Figure 5. Example of validation by Sanger’s sequencing of a SNV specific to sporadic Alzheimer disease 
and found in the X chromosome by method C. This figure shows a representative example of the read 
coverage (left part) and Sanger’s sequencing (right part) for a representative locus found in the X chromosome, 
in ATXN3L, by method C, an approach used to determine SNVs specific to sporadic Alzheimer disease (see 
methods). The results obtained by Sanger’s sequencing validate in every case both the presence of the SNV 
and its genotype (homozygous or heterozygous). C1–C3 correspond to non-demented controls and A1–A5 
correspond to AD patients.
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